Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Aeon Biopharma Inc’s profitability metrics reveal strong financial health. The company currently boasts a gross margin of -92.52%. The profit margin, also known as the revenue ratio or gross profit ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Global healthcare private equity (PE) deal value surged to an estimated $115 billion in 2024, marking the second-highest ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...

There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with ...